Current News

Walbrook PR, which provides high quality Financial PR and Investor Relations to Small Cap and AIM listed companies, announces its appointment as Financial PR & Investor Relations advisor to ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics. The team at Walbrook will manage the Company’s communications with the financial media, research analysts and non-institutional investors, including new and existing private investors.

ReNeuron is a leading, clinical-stage stem cell business, harnessing its unique stem cell technologies to develop ‘off the shelf’ stem cell treatments, without the need for immunosuppressive drugs. The Company’s lead cell therapy candidate is in clinical development for the blindness-causing disease, retinitis pigmentosa.

ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the brain. Additionally, the Company has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make any tissue cells of choice; in-house programmes are focused on treatments for blood cancers and diabetes.

Paul McManus, Founder and Managing Director of Walbrook PR, commented: “Reneuron is one of the leading players in the gene and cell therapy sector and with a promising pipeline and strong cash position, it is an exciting time for the Company. We look forward to working with the ReNeuron team and supporting the Company in its further success.”

For more information visit the Company’s website: http://www.reneuron.com/

For further information please contact:

About Walbrook PR:                                                                                                                                            www.walbrookpr.com

Walbrook PR was founded in April 2009 by Paul McManus and focuses on providing high quality Financial PR and Investor Relations to Small Cap and AIM listed companies.

Walbrook PR is ranked 2nd in the AIM Adviser Rankings guide and is ranked 7th by total number of Stock Market listed clients. Walbrook acts for 56 listed companies (mainly AIM) across a wide mix of sectors and is ranked 1st in Healthcare and 4th in Technology, by number of AIM clients.